Researchers from Utah are studying the efficiency of nasal spray, treated with antihistamine, at the cellular cultures infected with SARS-CoV-2, the virus that causes COVID-19.
Preliminary results of a new study in vitro (in vitro) showedthat the maleate chlorpheniramine – over-the-counter anti-inflammatory drug commonly used for relieving symptoms of allergies, colds or flu such as runny nose, sneezing, itchy and watery eyes – can reduce the presence of infection in conjunction with a nasal spray. Previous studies have shown that chlorpheniramine maleate (CPM) also acts as antiviral agent against different strains of flu.
An antihistamine was United with the nasal spray, which is currently being developed as a tool against allergiesand was introduced in the samples of infected cells. After 25 minutes of contact data showed a decrease in measurements of the virus in samples of cells to the extent that the researchers consider statistically significant.
Due to the concentrated presence of coronavirus in nasal tissue drug administration via nasal spray can be useful to ensure maximum impact.
However, further testing to accurately assess the effectiveness of the method in the treatment of patients with coronavirus.
Management on sanitary inspection behind quality of foodstuff and medicines USA (FDA) approved CPM for oral administration, and its main side effect is drowsiness.
“We remind you that there are no drugs or other therapeutic agents approved for the prevention or treatment of COVID-19, – reads the statement of the Centers for control and prevention (CDC), published 13 APR. – The current clinical management includes supportive care, including extra oxygen and mechanical ventilation support when needed.”